GC Biopharma Corp
Clinical trials sponsored by GC Biopharma Corp, explained in plain language.
A biopharmaceutical company developing plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new vaccine shield against COVID-19? a trial aims to find out Results expected May 2027 (estimated)
- Can a direct brain infusion slow sanfilippo syndrome? Results expected Jun 2027 (estimated)
- New chickenpox vaccine shows promise in large Kids' trial Results expected Aug 2027 (estimated)
-
New chickenpox vaccine shows promise in large Kids' trial
Vaccine Recruiting nowThis study tests a new chickenpox vaccine called MG1111 in healthy children aged 1 to 12 years. About 474 kids will receive either the new vaccine or the current one (Varivax) to compare safety and immune response. Participants will be followed for 42 days after each dose, and up…
Phase 3 • Sponsor: GC Biopharma Corp • Aim: Vaccine
Last updated Jun 27, 2026 12:09 UTC
-
New hope for fabry patients: experimental drug enters human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called HM15421/GC1134A in 18 adults with Fabry disease, a rare genetic disorder. The study aims to check the drug's safety, how the body processes it, and whether it can help control the disease. Participants receive the drug…
Phase 1/2 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC